加味玉屏风散的抗肝癌效应及机制  

Anti-liver cancer effects of Jiawei Yupingfeng San and related mechanisms

作　　者：张明慧 王宗傲 孙华 欧阳怡然 赵兰美 张婷[2] 姚霏[3] 袁琴[3] 江国荣[3] 张露蓉[3] 刘敏[1] ZHANG Minghui;WANG Zongao;SUN Hua;OUYANG Yiran;ZHAO Lanmei;ZHANG Ting;YAO Fei;YUAN Qin;JIANG Guorong;ZHANG Lurong;LIU Min(Suzhou Hospital of Traditional Chinese Medicine Affiliated to Nanjing University of Chinese Medicine,Suzhou 215009,Jiangsu Province,China;Department of Oncology,Suzhou Hospital of Traditional Chinese Medicine Affiliated to Nanjing University of Chinese Medicine,Suzhou 215009,Jiangsu Province,China;Central Laboratory of Suzhou Hospital of Traditional Chinese Medicine Affiliated to Nanjing University of Chinese Medicine,Suzhou 215009,Jiangsu Province,China)

机构地区：[1]南京中医药大学附属苏州市中医医院,江苏苏州215009 [2]南京医药大学附属苏州市中医医院肿瘤科,江苏苏州215009 [3]南京医药大学附属苏州市中医医院中心实验室,江苏苏州215009

出　　处：《新乡医学院学报》2025年第3期169-177,共9页Journal of Xinxiang Medical University

基　　金：国家自然科学基金项目(编号:81303276);苏州市科技计划项目(编号:SS202083)。

摘　　要：目的探讨加味玉屏风散改善肝癌免疫状态、延缓肿瘤生长的效应和机制。方法将C57小鼠随机分为正常组、模型组、玉屏风散组、加味玉屏风散组和索拉菲尼组,模型组、玉屏风散组、加味玉屏风散组和索拉菲尼组小鼠使用Hepa1-6肝癌细胞制备肝癌模型,造模成功后玉屏风散组小鼠灌胃给予玉屏风散颗粒(每千克体质量7.8 g),加味玉屏风散组小鼠灌胃给予加味玉屏风散颗粒(每千克体质量7.8 g),索拉菲尼组腹腔注射给予索拉非尼(每千克体质量1 mg),连续给药2周。然后,5组小鼠经眼眶取血,置于含100μL抗凝剂取血管中;脱颈处死小鼠,取4组荷瘤小鼠的肿瘤组织及癌旁组织、胸腺、脾脏,以及正常组小鼠的肝脏、胸腺、脾脏;称量肿瘤组织、胸腺、脾脏质量,并计算肿瘤抑制率、脾脏指数、胸腺指数;采用流式细胞术检测小鼠外周血淋巴细胞、肿瘤组织、癌旁组织的淋巴细胞免疫表型;采用酶联免疫吸附试验检测小鼠血清、肿瘤组织和癌旁组织中胸腺基质淋巴细胞生成素(TSLP)水平。结果玉屏风散组、加味玉屏风散组及索拉非尼组小鼠肿瘤质量显著低于模型组,加味玉屏风散组和索拉非尼组小鼠肿瘤质量显著低于玉屏风散组(P<0.05)。加味玉屏风散组和索拉非尼组小鼠肿瘤抑制率显著高于玉屏风散组(P<0.05)。模型组小鼠脾脏质量、脾脏指数、胸腺质量及胸腺指数显著低于正常组(P<0.05)。玉屏风散组和加味玉屏风散组小鼠脾脏质量、脾脏指数与胸腺质量均显著高于模型组(P<0.05);玉屏风散组小鼠胸腺指数显著高于模型组(P<0.05);索拉菲尼组小鼠脾脏指数显著高于模型组(P<0.05);加味玉屏风散组小鼠脾脏质量和脾脏指数显著低于玉屏风散组(P<0.05);玉屏风散组小鼠肿瘤组织、癌旁组织和外周血中CD8^(+)T淋巴细胞比例显著高于模型组(P<0.05);加味玉屏风散组小鼠癌旁组织和外周血Objective To investigate whether and how Jiawei Yupingfeng San improve the immune status of liver cancer.Methods C57 mice were randomly divided into a normal group,a model group,a Yupingfeng San group,a Jiawei Yupingfeng San group and a Sorafenib group.Hepa1-6 hepatocellular carcinoma cells were used to construct liver cancer mouse models in the model,Yupingfeng San,Jiawei Yupingfeng San and Sorafenib groups.After modeling,mice in Yupingfeng San and Jiawei Yupingfeng San groups were given Yupingfeng San granules(7.8 g·kg-1)and Jiawei Yupingfeng San granules(7.8 g·kg-1)by intragastric infusion,respectively.Mice in the Sorafenib group were given sorafenib(1 g·kg-1)by intraperitoneal injection.For these three groups,the drug was administered continuously for 2 weeks.Then,blood was collected from the five groups of mice via the eye socket and placed in a blood vessel containing 100μL of anticoagulant.Afterwards,the mice were killed by decapitation,and tumor and paracancerous tissues,the thymus gland,and the spleen were collected from the four groups of tumor-bearing mice.The liver,thymus gland,and spleen were collected from the mice in the normal group.The masses of tumor tissues,the thymus gland,and the spleen were weighed,and the tumor inhibition rate,spleen index,and thymus gland index were calculated.The immunophenotypes of the lymphocytes of peripheral blood,tumor and paracancerous tissues were tested by flow cytometry.Enzyme-linked immunosorbent assay(ELISA)was used to detect the level of thymic stromal lymphopoietin(TSLP)in mouse serum,tumor and paracancerous tissues.Results The tumor mass of Yupengfeng San,Jiawei Yupingfeng San and Sorafenib groups was significantly lower than that of the model group(P<0.05).The tumor mass of Jiawei Yupingfeng San and Sorafenib groups was significantly lower than that of the Yupengfeng San group(P<0.05).The tumor inhibition rate of Jiawei Yupingfeng San and Sorafenib groups was significantly higher than that in the Yupingfeng San group(P<0.05).The spleen mass,spleen index

关 键 词：肝癌 胸腺基质淋巴细胞生成素 加味玉屏风散 

分 类 号：R285.5[医药卫生—中药学] R735.7[医药卫生—中医学]